Contributions
Abstract: EP1525
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Background: Neurodegeneration, in particular of the grey matter (GM), is one of the pathological hallmarks of multiple sclerosis (MS) and it represents one of the target outcomes of current therapeutic strategies for these patients. Several software tools for GM and brain atrophy measurement on MRI are currently available.
Aims: The aim of this study was the comparison of different methods [Advanced Normalization Tools (ANTs) version 1.9, FSL-SIENAx/SIENA 5.0.1, Icometrix-MSmetrix 1.7, and SPM version 12] currently used for GM and brain atrophy estimation on MR images of MS patients.
Methods: The dataset arranged consisted of 3D-T1 and 3D-T2FLAIR sequences of in-house simulated data, healthy controls' longitudinal data, test and retest MRI of MS patients acquired at different MR scanner field strengths and manufacturers, and MS patients' longitudinal data (1 year follow-up). Cross-sectional and longitudinal GM and brain atrophy estimation were tested for each software, with and without T1-hypointense lesion filling. Accuracy and precision between the pipelines were compared. Paired t-tests were used to statistically compare the different results.
Results: The mean accuracy in GM and brain volume estimation for each method was: ANTs=0.96-0.96, FSL-SIENAX=0.95-0.96, MSmetrix=0.87-0.89 and SPM=0.97-0.96. The mean error in GM and brain atrophy measure was respectively: ANTs=0.52-0.11%, FSL-SIENAX=0.11%, MSmetrix=0.16-0.15% and SPM=0.09-0.1%. Except for ANTs (p< 0.001), all softwares showed significant precision in GM and brain volume estimation between scan and rescan on both 1.5T and 3T scanners (p>0.05). However, all methods showed significant differences (p< 0.05) when comparing tissue volume measurements between 1.5T and 3T scanners, and, except for SPM pipeline, among 3T manufacturers. For longitudinal atrophy, only ANTs was sensitive to different manufacturers and field strength acquisitions. Lesion filling significantly influenced longitudinal assessment of GM and brain atrophy for ANTs (p< 0.05), while for SPM and MSmetrix it only affected GM atrophy measure.
Conclusions: Accuracy and precision between available software were evaluated and compared for different settings. The results of this work could help in the selection of the suitable pipeline among the available ones, according to the need of the analysis framework (research center, clinical setting or clinical trial), privileging in one case high accuracy rather than high reliability or vice versa.
Disclosure:
L. Storelli, E. Pagani, W. van Hecke have nothing to disclose.
M.A. Rocca received speakers honoraria from Biogen Idec, Novartis, Teva Neurosciences and Genzyme and receives research support from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla.
N. de Stefano has received honoraria from Schering, Biogen Idec, Teva Pharmaceutical Industries, Novartis, Genzyme, and Merck Serono SA for consulting services, speaking, and travel support. He serves on advisory boards for Biogen Idec, Merck Serono SA, and Novartis.
A. Rovira serves on scientific advisory boards for Biogen Idec, Novartis, Genzyme, and OLEA Medical, has received speaker honoraria from Bayer HealthCare Pharmaceuticals, Genzyme, Bracco, Merck Serono, Teva Pharmaceutical Industries, OLEA Medical, Stendhal, Novartis, and Biogen Idec, and has research agreements with Siemens AG.
J Sastre-Garriga has received compensation for serving on scientific advisory boards or on speaker´s bureaus from Biogen Idec, Merck Serono, Novartis, Teva Pharmaceutical Industries, and Sanofi-Aventis.
J. Palace reports personal fees from Biogen Idec, Teva Pharmaceutical Industries, Merck Serono, Bayer Schering, Novartis, Chugai Pharma, Ono Pharmaceuticals Co, and CI consulting, and grants from Merck Serono, Bayer Schering, and Novartis.
M. Filippi is Editor-in-Chief of the Journal of Neurology; serves on a scientific advisory board for Teva Pharmaceutical Industries; has received compensation for consulting services and/or speaking activities from Biogen Idec, Merck-Serono, Novartis, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer´s Drug Discovery Foundation (ADDF), the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione Italiana di Ricerca per la SLA).
Abstract: EP1525
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 21 Imaging
Background: Neurodegeneration, in particular of the grey matter (GM), is one of the pathological hallmarks of multiple sclerosis (MS) and it represents one of the target outcomes of current therapeutic strategies for these patients. Several software tools for GM and brain atrophy measurement on MRI are currently available.
Aims: The aim of this study was the comparison of different methods [Advanced Normalization Tools (ANTs) version 1.9, FSL-SIENAx/SIENA 5.0.1, Icometrix-MSmetrix 1.7, and SPM version 12] currently used for GM and brain atrophy estimation on MR images of MS patients.
Methods: The dataset arranged consisted of 3D-T1 and 3D-T2FLAIR sequences of in-house simulated data, healthy controls' longitudinal data, test and retest MRI of MS patients acquired at different MR scanner field strengths and manufacturers, and MS patients' longitudinal data (1 year follow-up). Cross-sectional and longitudinal GM and brain atrophy estimation were tested for each software, with and without T1-hypointense lesion filling. Accuracy and precision between the pipelines were compared. Paired t-tests were used to statistically compare the different results.
Results: The mean accuracy in GM and brain volume estimation for each method was: ANTs=0.96-0.96, FSL-SIENAX=0.95-0.96, MSmetrix=0.87-0.89 and SPM=0.97-0.96. The mean error in GM and brain atrophy measure was respectively: ANTs=0.52-0.11%, FSL-SIENAX=0.11%, MSmetrix=0.16-0.15% and SPM=0.09-0.1%. Except for ANTs (p< 0.001), all softwares showed significant precision in GM and brain volume estimation between scan and rescan on both 1.5T and 3T scanners (p>0.05). However, all methods showed significant differences (p< 0.05) when comparing tissue volume measurements between 1.5T and 3T scanners, and, except for SPM pipeline, among 3T manufacturers. For longitudinal atrophy, only ANTs was sensitive to different manufacturers and field strength acquisitions. Lesion filling significantly influenced longitudinal assessment of GM and brain atrophy for ANTs (p< 0.05), while for SPM and MSmetrix it only affected GM atrophy measure.
Conclusions: Accuracy and precision between available software were evaluated and compared for different settings. The results of this work could help in the selection of the suitable pipeline among the available ones, according to the need of the analysis framework (research center, clinical setting or clinical trial), privileging in one case high accuracy rather than high reliability or vice versa.
Disclosure:
L. Storelli, E. Pagani, W. van Hecke have nothing to disclose.
M.A. Rocca received speakers honoraria from Biogen Idec, Novartis, Teva Neurosciences and Genzyme and receives research support from the Italian Ministry of Health and Fondazione Italiana Sclerosi Multipla.
N. de Stefano has received honoraria from Schering, Biogen Idec, Teva Pharmaceutical Industries, Novartis, Genzyme, and Merck Serono SA for consulting services, speaking, and travel support. He serves on advisory boards for Biogen Idec, Merck Serono SA, and Novartis.
A. Rovira serves on scientific advisory boards for Biogen Idec, Novartis, Genzyme, and OLEA Medical, has received speaker honoraria from Bayer HealthCare Pharmaceuticals, Genzyme, Bracco, Merck Serono, Teva Pharmaceutical Industries, OLEA Medical, Stendhal, Novartis, and Biogen Idec, and has research agreements with Siemens AG.
J Sastre-Garriga has received compensation for serving on scientific advisory boards or on speaker´s bureaus from Biogen Idec, Merck Serono, Novartis, Teva Pharmaceutical Industries, and Sanofi-Aventis.
J. Palace reports personal fees from Biogen Idec, Teva Pharmaceutical Industries, Merck Serono, Bayer Schering, Novartis, Chugai Pharma, Ono Pharmaceuticals Co, and CI consulting, and grants from Merck Serono, Bayer Schering, and Novartis.
M. Filippi is Editor-in-Chief of the Journal of Neurology; serves on a scientific advisory board for Teva Pharmaceutical Industries; has received compensation for consulting services and/or speaking activities from Biogen Idec, Merck-Serono, Novartis, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer´s Drug Discovery Foundation (ADDF), the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione Italiana di Ricerca per la SLA).